Latest MediciNova News & Updates

See the latest news and media coverage for MediciNova. We track all announcements, press releases, and industry mentions in real time, all in one place.

MediciNova

Biopharmaceutical company focused on neurology, respiratory, and liver diseases

medicinova.com

Headquarters: La Jolla, United States
Company type: Public company
Number of employees: 15–50
Industry: Pharmaceuticals

Last updated Today

Latest news about MediciNova

In short: MediciNova advanced its clinical pipeline for ALS, MS, and oncology while achieving key enrollment milestones and reporting fiscal losses.

Company announcements

July 31 MediciNova

MediciNova completes enrollment of 200 patients in ALS study

The SEANOBI-ALS trial for MN-166 (ibudilast) reached full enrollment, advancing potential new treatment for ALS.

June 30 MediciNova

MediciNova CEO updates shareholders on clinical milestones

MN-001 Phase 2 trial completed, MN-166 patent allowed, ALS enrollment at 50%.

June 8 MediciNova

MediciNova receives patent allowance for MN-166 combination therapy

The patent covers use with anti-PD-1 antibodies for glioblastoma treatment, expiring in 2042.

May 13 MediciNova

MediciNova is advancing MN‑166 for ALS treatment

The drug targets neuroinflammatory pathways to slow disease progression and preserve motor function.

Media coverage

July 15 Yahoo

MediciNova achieves target enrolment in SEANOBI-ALS study of MN-166

MediciNova has achieved the target enrolment of 200 patients in the SEANOBI-ALS clinical study, evaluating MN-166 (ibudilast) for amyotrophic lateral sclerosis (ALS). The SEANOBI...

May 26 Stockhouse

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

LA JOLLA, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard...

May 15 Yahoo Finance

MN-166 Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan

MN-166 presents market opportunities through its multi-indication strategy, including ALS, MS, and more, supported by pivotal trials, regulatory incentives like Orphan Drug and Fast Track...

May 14 Yahoo Finance

MediciNova: Q1 Earnings Snapshot

MediciNova Inc. MNOV) on Thursday reported a loss of $2.6 million in its first quarter.

Never miss news about MediciNova

Track MediciNova and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

MediciNova competitors & trending companies

Browse news for competitors to MediciNova and other trending companies.